Fate Therapeutics Inc. (NASDAQ:FATE)’s share price fell 5.4% during trading on Tuesday . The company traded as low as $2.31 and last traded at $2.45, with a volume of 464,166 shares. The stock had previously closed at $2.59.

A number of research firms have commented on FATE. BMO Capital Markets set a $4.00 price objective on Fate Therapeutics and gave the stock a “buy” rating in a research note on Monday. HC Wainwright began coverage on Fate Therapeutics in a research note on Thursday, July 28th. They set a “buy” rating and a $9.00 price objective on the stock. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Leerink Swann restated an “outperform” rating and set a $4.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, June 21st. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, May 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $6.17.

The firm’s market cap is $72.45 million. The stock’s 50-day moving average is $1.85 and its 200 day moving average is $1.84.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03. The business earned $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Equities research analysts expect that Fate Therapeutics Inc. will post ($1.23) earnings per share for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.